A fungal epidemic amidst a viral pandemic: Risk factors for development of COVID-19 associated rhino-orbital-cerebral mucormycosis in India.
Varshitha Hemanth VasanthapuramRoshmi GuptaNamrata AdulkarAkshay Gopinathan NairRenuka A BradooRaghuraj HegdeUsha SinghSameeksha TadepalliBipasha MukherjeeSaurabh KamalMd Shahid AlamRaksha RaoSushma AnanthakrishnaVarsha BackiavathyAjay Krishna MurthyLynn D'CunhaGagan DudejaAnnie JojiAnjali KiranKirti KokaMoupia Goswami MukhopadhyaySonam Poonam NisarPriyanka R RaoChhaya A ShindePublished in: Orbit (Amsterdam, Netherlands) (2022)
Male gender, active COVID-19 infection, moderate or severe COVID-19, uncontrolled diabetes, steroid administration during COVID-19 treatment are risk factors for developing rhino-orbital-cerebral mucormycosis. Vaccination is protective. Random blood sugar of >178 mg/dl in COVID-19 positive or recovered patients should warrant close observation and early detection of ROCM. Presence of ophthalmoplegia, blepharoptosis at first clinical presentation and orbital apex involvement on imaging are associated with intracranial extension in ROCM.
Keyphrases
- sars cov
- coronavirus disease
- respiratory syndrome coronavirus
- subarachnoid hemorrhage
- ejection fraction
- end stage renal disease
- type diabetes
- newly diagnosed
- cardiovascular disease
- early onset
- prognostic factors
- mental health
- high intensity
- skeletal muscle
- metabolic syndrome
- patient reported outcomes
- blood brain barrier
- adipose tissue
- drug induced
- weight loss